We provide you with 20 years of free, institutional-grade data for CDAK stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CDAK. Explore the full financial landscape of CDAK stock.
| Reported Date | CIK | Ticker | Type |
|---|
Codiak BioSciences, Inc(NASDAQ:CDAK) 
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an ...
Website: https://www.codiakbio.com/
Founded: 2015
Full Time Employees: 105 (May 2021)
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about CDAK stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.